Eli Lilly (LLY) Stock Hits $1,230 in June 2026 — Strong Sales of Mounjaro & Zepbound Drive Gains

Eli Lilly company stock maintained its upward trend and is still showing good performance on the day. However, the upward trend...

Written by: Arslan Butt • Tuesday, June 30, 2026 • 2 min read

• Last updated: Tuesday, June 30, 2026

Quick overview

Eli Lilly's stock continues to rise, driven by strong sales of its weight loss and diabetes medications.
The company reported $8.7 billion in sales from Mounjaro, a 125% increase from last year, and $4.1 billion from Zepbound, an 80% increase.
Total sales for Eli Lilly reached $19.8 billion in three months, marking a 56% increase compared to the same period last year.
Due to this performance, Eli Lilly has raised its full-year sales targets to between $82 and $85 billion, boosting investor confidence.

Eli Lilly company stock maintained its upward trend and is still showing good performance on the day. However, the upward trend can be attributed to the tremendous sales of its popular weight loss and diabetes medicines.

Moreover, the latest development in the company about new deals and new treatments was also seen as a positive factor for this stock’s performance.

However, the medicines of this company are in very high demand all over the world because many people are suffering from diabetes and want to lose weight. Therefore, both doctors and patients are liking these medicines. As a result, the sales of Mounjaro and Zepbound are increasing very fast.

At the time we are writing this article, the stock is at the $1,229 level, showing more than 1 percent gains on the day.

Eli Lilly Sales Keep Growing and Future Looks Very Strong

However, the companys excellent performance is also evidenced by its strong earnings report for the first three months of 2026, which shows that the company made 8.7 billion dollars in sales from the medicine Mounjaro, which is 125 percent more than last year.

Eli Lilly (LLY) Stock Price Chart - Source: Tradingview — Eli Lilly (LLY) Stock Price Chart – Source: Tradingview

In addition, sales of the weight loss medicine Zepbound also increased by 80 percent, reaching 4.1 billion dollars. As a result of these tremendous sales of these two medicines, the total sales of the entire Eli Lilly company reached 19.8 billion dollars in three months. This is 56 percent more than the same time last year.

These numbers show that the demand for the company’s medicines is increasing very rapidly and people are liking these medicines very much.

As a result of this excellent performance, the company has increased its full year 2026 targets. Now it expects that sales for the full year can reach 82 to 85 billion dollars. This is a very big positive signal because investors gain confidence from it that the companys future is very good. As sales increase, the company will earn more profit and the stock price will also remain strong.

Check out our free forex signals
Follow the top economic events on FX Leaders economic calendar
Trade better, discover more Forex Trading Strategies
Open a FREE Trading Account
Read our latest reviews on: Avatrade, Exness, HFM and XM

ABOUT THE AUTHOR See More

Arslan Butt

Lead Markets Analyst – Multi-Asset (FX, Commodities, Crypto)

Arslan Butt serves as the Lead Commodities and Indices Analyst, bringing a wealth of expertise to the field. With an MBA in Behavioral Finance and active progress towards a Ph.D., Arslan possesses a deep understanding of market dynamics. His professional journey includes a significant role as a senior analyst at a leading brokerage firm, complementing his extensive experience as a market analyst and day trader. Adept in educating others, Arslan has a commendable track record as an instructor and public speaker. His incisive analyses, particularly within the realms of cryptocurrency and forex markets, are showcased across esteemed financial publications such as ForexCrunch, InsideBitcoins, and EconomyWatch, solidifying his reputation in the financial community.